Bill Text: IL HB4055 | 2023-2024 | 103rd General Assembly | Engrossed
Bill Title: Amends the Prior Authorization Reform Act. Provides that notwithstanding any other provision of law, a health insurance issuer or a contracted utilization review organization may not require a prior authorization for drug therapies approved by the U.S. Food and Drug Administration for the treatment of hereditary bleeding disorders any more frequently than 6 months or the length of time the prescription for that dosage remains valid, whichever period is shorter. Effective January 1, 2026.
Spectrum: Moderate Partisan Bill (Republican 9-1)
Status: (Engrossed) 2024-04-30 - Rule 2-10 Committee Deadline Established As May 10, 2024 [HB4055 Detail]
Download: Illinois-2023-HB4055-Engrossed.html
| |||||||
| |||||||
| 1 | AN ACT concerning regulation.
| ||||||
| 2 | Be it enacted by the People of the State of Illinois, | ||||||
| 3 | represented in the General Assembly:
| ||||||
| 4 | Section 5. The Prior Authorization Reform Act is amended | ||||||
| 5 | by adding Section 77 as follows:
| ||||||
| 6 | (215 ILCS 200/77 new) | ||||||
| 7 | Sec. 77. Prior authorization for drug therapies for | ||||||
| 8 | hereditary bleeding disorders. Notwithstanding any other | ||||||
| 9 | provision of law, a health insurance issuer or a contracted | ||||||
| 10 | utilization review organization may not require a prior | ||||||
| 11 | authorization for drug therapies approved by the U.S. Food and | ||||||
| 12 | Drug Administration for the treatment of hereditary bleeding | ||||||
| 13 | disorders any more frequently than 6 months or the length of | ||||||
| 14 | time the prescription for that dosage remains valid, whichever | ||||||
| 15 | period is shorter.
| ||||||
